{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+B+Cell", "query": { "condition": "Lymphoma, B Cell" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2588, "total_pages": 259, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+B+Cell&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T15:25:36.315Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05794958", "title": "Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Large B-cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-05-23", "completion_date": "2038-04-01", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05794958" }, { "nct_id": "NCT02440685", "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Lymphoma, Follicular", "Cancer", "Neoplasm", "Tumor", "Lymphoma, Malignant", "Lymphoma, B-cell", "Lymphoma, Non-Hodgkin", "B-Cell Chronic Lymphocytic Leukemia", "B-Cell Leukemia, Chronic", "B-Lymphocytic Leukemia, Chronic", "Chronic Lymphocytic Leukemia", "Leukemia, Lymphocytic, Chronic", "Leukemia, Lymphocytic, Chronic, B Cell", "Myelofibrosis", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "Lymphoma, T Cell, Peripheral", "Peripheral T-Cell Lymphoma", "T-Cell Lymphoma, Peripheral" ], "interventions": [ { "name": "ASN002 Dose Escalation", "type": "DRUG" }, { "name": "ASN002 RD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2015-05", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 12, "location_summary": "Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02440685" }, { "nct_id": "NCT00759603", "title": "Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2008-09", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-08-27", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00759603" }, { "nct_id": "NCT03914625", "title": "A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma", "Down Syndrome" ], "interventions": [ { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Mercaptopurine Oral Suspension", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "365 Days", "maximum_age": "31 Years", "sex": "ALL", "summary": "365 Days to 31 Years" }, "enrollment_count": 6720, "start_date": "2019-07-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 201, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914625" }, { "nct_id": "NCT00755040", "title": "Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "cyclosporine ophthalmic emulsion", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2008-10", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 5, "location_summary": "Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00755040" }, { "nct_id": "NCT05621096", "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "DLBCL - Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Follicular Lymphoma", "Mediastinal Large B-cell Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Bridging radiation therapy", "type": "RADIATION" }, { "name": "Liso-cel", "type": "BIOLOGICAL" }, { "name": "Post-infusion radiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 33, "start_date": "2023-03-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05621096" }, { "nct_id": "NCT00352443", "title": "S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2006-09", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 6, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352443" }, { "nct_id": "NCT03749018", "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Indolent Non-Hodgkin Lymphoma", "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-01-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749018" }, { "nct_id": "NCT06708897", "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL / SLL", "CLL (Chronic Lymphocytic Leukemia)", "SLL (Small Lymphocytic Lymphoma)", "Marginal Zone Lymphoma(MZL)", "Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Lonitoclax (ZE50-0134)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lomond Therapeutics Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2025-04-08", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 5, "location_summary": "Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06708897" }, { "nct_id": "NCT00052520", "title": "Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Polycythemia Vera", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "staining method", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2002-09", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-09-08T15:25:36.315Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052520" } ] }